Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.

BMC cancer - 6 Jun 2024

Xu Jing-Xuan, Zhu Qi-Long, Bi Yu-Miao, Peng Yu-Chong

Abstract excerpt

PURPOSE: The potential efficacy of metformin in breast cancer (BC) has been hotly discussed but never conclusive. This genetics-based study aimed to evaluate the relationships between metformin targets and BC risk. METHODS: Metformin targets from DrugBank and genome-wide association study (GWAS) data from IEU OpenGWAS and FinnGen were used to investigate the breast cancer (BC)-metformin causal link with various...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Chemotherapy, Adjuvant
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Hypoglycemic Agents

Share to Mendelian Randomization Analysis

Share to Metformin

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 38844880
DOI: 10.1186/s12885-024-12453-w
PMCID: PMC11155042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.PMID 38844880Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

Metformin for the treatment of breast cancer: a scoping review of randomized clinical trialsSemantic proximity Read ↗

Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysisSemantic proximity Read ↗

Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.Semantic proximity Read ↗

Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.Semantic proximity Read ↗

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.Semantic proximity Read ↗

Antihypertensive drug targets and breast cancer risk: a two-sample Mendelian randomization study.Semantic proximity Read ↗

Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study.Semantic proximity Read ↗

Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes.Semantic proximity Read ↗

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates.Semantic proximity Read ↗

Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.Semantic proximity Read ↗

Metformin pathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.